Teva Chosen As 'Bellwether' In US Price-Fixing Litigation
Case Involving Israeli Generics Giant Selected As Priority For Trial
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.
You may also be interested in...
Teva has struck a $950,000 deal to settle US price-fixing litigation with the state of Mississippi, in what the firm anticipates could be the first of multiple settlements with individual US states.
Facing civil and criminal charges over alleged price fixing in the US, Teva looks to have succeeded in removing itself from the spotlight in the civil proceedings, having previously been selected as a priority for trial. CEO Kåre Schultz weighed in on the latest development.
Fresh details have been revealed in the ongoing saga of US generic price-fixing litigation, with a newly-published unredacted complaint disclosing excerpts from a notebook alleged to contain details of anti-competitive conduct.